Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | Director | November 08, 2021 | November 08, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date November 08, 2021 · Filed November 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,932 |
Last balance in matching sequence
After 2021-11-08 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2021-11-08 · Exercise / conversion · Acquired 22,302 · Balance 51,234 F1: Amount includes 3,128 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Row 2 · 2021-11-08 · Sale · Disposed 22,302 · Balance 28,932 F1: Amount includes 3,128 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Row 3 · 2021-11-08 · Exercise / conversion · Acquired 4,166 · Balance 33,098 F1: Amount includes 3,128 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Row 4 · 2021-11-08 · Sale · Disposed 4,166 · Balance 28,932 F1: Amount includes 3,128 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.02 · Expires 2023-01-02 | Direct | 0 |
Reported balance
After 2021-11-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-11-08 · Exercise / conversion · Disposed 22,302 · Balance 0 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.46 · Expires 2022-05-22 | Direct | 0 |
Reported balance
After 2021-11-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-11-08 · Exercise / conversion · Disposed 4,166 · Balance 0 |
| Common StockSEC Table I · non-derivative | Indirectby Spouse | 1,850 |
Reported balance
Holding disclosure · report date 2021-11-08 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 1,850 |
Filing footnotes · ownership attribution and instrument terms
F1: Amount includes 3,128 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
TETRAPHASE PHARMACEUTICALS INC
Report date July 28, 2020 · Filed July 29, 2020
Section 16 reporting ended · disclosed 2020-07-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-07-28 transaction · row 1
1 source rowRow 1 · 2020-07-28 · Other · Disposed 1,944 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger, dated as of June 24, 2020, by and among Tetraphase Pharmaceuticals, Inc., TTP Merger Sub, Inc. and La Jolla Pharmaceutical Company (the "Merger Agreement"), these shares were tendered and disposed of at the Acceptance Time (all terms capitalized but not defined shall have the meaning given to them in the Merger Agreement) in exchange for the right to receive (i) $2.00 per Share (the "Cash Consideration"), to the holder in cash, without interest and less any applicable withholding taxes, plus (ii) one non-transferable contractual contingent value right per Share (a "CVR") representing the right to receive certain consideration based on the achievement of net sales milestones. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 0 |
Reported balance
After 2020-07-28 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2020-07-28 · Other · Disposed 191 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger, dated as of June 24, 2020, by and among Tetraphase Pharmaceuticals, Inc., TTP Merger Sub, Inc. and La Jolla Pharmaceutical Company (the "Merger Agreement"), these shares were tendered and disposed of at the Acceptance Time (all terms capitalized but not defined shall have the meaning given to them in the Merger Agreement) in exchange for the right to receive (i) $2.00 per Share (the "Cash Consideration"), to the holder in cash, without interest and less any applicable withholding taxes, plus (ii) one non-transferable contractual contingent value right per Share (a "CVR") representing the right to receive certain consideration based on the achievement of net sales milestones. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of that certain Agreement and Plan of Merger, dated as of June 24, 2020, by and among Tetraphase Pharmaceuticals, Inc., TTP Merger Sub, Inc. and La Jolla Pharmaceutical Company (the "Merger Agreement"), these shares were tendered and disposed of at the Acceptance Time (all terms capitalized but not defined shall have the meaning given to them in the Merger Agreement) in exchange for the right to receive (i) $2.00 per Share (the "Cash Consideration"), to the holder in cash, without interest and less any applicable withholding taxes, plus (ii) one non-transferable contractual contingent value right per Share (a "CVR") representing the right to receive certain consideration based on the achievement of net sales milestones.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2017 Filed Sep 1, 2017 23:21 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 500 | $14.73 | $7,362.50 |
DisclosureSEC source: 0001061983-17-000055 · edgardoc.xml · nonDerivative · entry 6 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,600 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2017. Read SEC document |
| September 01, 2017 Filed Sep 1, 2017 23:21 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 900 | $14.70 | $13,230.00 |
DisclosureSEC source: 0001061983-17-000055 · edgardoc.xml · nonDerivative · entry 5 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,100 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2017. Read SEC document |
| September 01, 2017 Filed Sep 1, 2017 23:21 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 600 | $14.68 | $8,805.00 |
DisclosureSEC source: 0001061983-17-000055 · edgardoc.xml · nonDerivative · entry 4 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2017. Read SEC document |
| September 01, 2017 Filed Sep 1, 2017 23:21 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,100 | $14.65 | $16,115.00 |
DisclosureSEC source: 0001061983-17-000055 · edgardoc.xml · nonDerivative · entry 3 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,600 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2017. Read SEC document |
| September 01, 2017 Filed Sep 1, 2017 23:21 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 300 | $14.60 | $4,380.00 |
DisclosureSEC source: 0001061983-17-000055 · edgardoc.xml · nonDerivative · entry 2 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,700 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2017. Read SEC document |
| September 01, 2017 Filed Sep 1, 2017 23:21 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 5,000 | $4.02 | $20,100.00 |
DisclosureSEC source: 0001061983-17-000055 · edgardoc.xml · nonDerivative · entry 1 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2017. Read SEC document |
| August 29, 2017 Filed Aug 30, 2017 23:29 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $4.02 | $0.00 |
DisclosureSEC source: 0001061983-17-000050 · edgardoc.xml · derivative · entry 4 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,302 Underlying: Common Stock · 5,000 shares Expires 2023-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 29, 2017 Filed Aug 30, 2017 23:29 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 5,000 | $14.00 | $70,000.00 |
DisclosureSEC source: 0001061983-17-000050 · edgardoc.xml · nonDerivative · entry 2 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2017. Read SEC document |
| August 29, 2017 Filed Aug 30, 2017 23:29 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 5,000 | $4.02 | $20,100.00 |
DisclosureSEC source: 0001061983-17-000050 · edgardoc.xml · nonDerivative · entry 1 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2017. Read SEC document |
| May 31, 2017 Filed Jun 1, 2017 17:02 UTC | TETRAPHASE PHARMACEUTICALS INC TTPH · Entity 147285 | GrantStock option (right to buy) · Derivative | 12,500 | $0.00 Strike: $6.89 | $0.00 |
DisclosureSEC source: 0001209191-17-036841 · doc4.xml · derivative · entry 1 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2027-05-30 F1 · derivative.exercise_date: Vests in equal quarterly installments over a one-year period measured from the date of grant. Read SEC document |
| May 18, 2017 Filed May 22, 2017 21:56 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $14.25 | $0.00 |
DisclosureSEC source: 0001061983-17-000030 · edgardoc.xml · derivative · entry 1 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-05-18 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on May 18, 2018. Read SEC document |
| March 15, 2017 Filed Mar 16, 2017 16:22 UTC | TETRAPHASE PHARMACEUTICALS INC TTPH · Entity 147285 | PurchaseCommon Stock | 1,000 | $7.47 | $7,470.00 |
DisclosureSEC source: 0001209191-17-021089 · doc4.xml · nonDerivative · entry 2 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 3,825 Read SEC document |
| March 15, 2017 Filed Mar 16, 2017 16:22 UTC | TETRAPHASE PHARMACEUTICALS INC TTPH · Entity 147285 | PurchaseCommon Stock | 10,000 | $7.49 | $74,900.00 |
DisclosureSEC source: 0001209191-17-021089 · doc4.xml · nonDerivative · entry 1 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.